Group 1 - The core announcement is about a senior management reshuffle at Stone Pharmaceutical Group, effective from December 19, 2025 [1] - Zhang Cuilong will no longer serve as Vice Chairman, CEO, and Authorized Representative but will remain an Executive Director [1] - Cai Lei has been appointed as Vice Chairman, Executive Director, CEO, and Authorized Representative, while Wei Qingjie has been appointed as Vice Chairman, Executive Director, and COO [1] Group 2 - Cai Lei, aged 45, joined the company in April 2014 and currently serves as Executive President and heads multiple departments, holding 40,000 shares with an annual salary of $17,000 and a director's fee of HKD 63,000 [1] - Cai Lei is the son of Cai Dongchen, the Chairman and major shareholder of Stone Pharmaceutical Group, and the brother of Executive Director Cai Xin [1] - Wei Qingjie, aged 56, joined the company in May 2019 and holds multiple key positions, owning 300,000 shares and 1.4 million unvested stock awards, with a monthly salary of HKD 60,000 and a director's fee of HKD 63,000 [1]
石药集团：董事会主席、执行董事及主要股东蔡东晨之子蔡磊接任CEO